The International Atomic Energy Agency (IAEA) randomized trial of palliative treatment of incurable locally advanced non small cell lung cancer (NSCLC) using radiotherapy (RT) and chemotherapy (CHT) in limited resource setting

Jeremic B 1 , Fidarova E 2 , Sharma V 3 , Faheem M 4 , Ameira AA 5 , Nasr Ben Ammar C 6 Show all authors , Frobe A 7 , Lau F 8 , Brincat S 9 , Jones G 10

Affiliations 

  • 1 Institute of Lung Diseases, Sremska Kamenica and BioIRC Research Centre, Kragujevac, Serbia. Electronic address: nebareje@gmail.com
  • 2 International Atomic Energy Agency, Vienna, Austria
  • 3 University of Witswatersrand, Johannesburg, South Africa
  • 4 Nuclear Medicine, Oncology and Radiotherapy Institute, Islamabad, Pakistan
  • 5 Misr Oncology Centre, Cairo, Egypt
  • 6 Institut National de Cancer Salah Azaiz, Tunis, Tunisia
  • 7 Sestre Milosrdnice Hospital, Zagreb, Croatia
  • 8 General Hospital, Kuala Lumpur, Malaysia
  • 9 Sir Paul Boffa Hospital, La Valetta, Malta
  • 10 University of Toronto, Canada
Radiother Oncol, 2015 Jul;116(1):21-6.
PMID: 26163093 DOI: 10.1016/j.radonc.2015.06.017

Abstract

To optimize palliation in incurable locally advanced non-small cell lung cancer (NSCLC), the International Atomic Energy Agency conducted a prospective randomized study (NCT00864331) comparing protracted palliative radiotherapy (RT) course with chemotherapy (CHT) followed by short-course palliative RT.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications